The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Patterns of PrEP continuation and coverage in the first year of use: a latent class analysis of a programmatic PrEP trial in Kenya
Open accessAbstract
Introduction: Effective PrEP use is critical for impact, but data are limited on common patterns of continuation and coverage among persons using PrEP in real‐world settings. Methods: Data are from the Partners Scale‐Up Project, a programmatic stepped‐wedge cluster‐randomized trial to integrate PrEP delivery in 25 Kenyan public health facilities conducted between February 2017 and December 2021. We evaluated PrEP continuation using visit attendance and pharmacy refill records, and computed medication possession ratio to define coverage during the first year of use. Latent class mixture models were used to identify and characterize membership to different PrEP continuation patterns. Multinomial logistic regression was used to examine the association between group trajectories and demographic and behaviour characteristics. Results: Overall, 4898 persons initiated PrEP, 54% (2640) were female, mean age was 33 years (standard deviation 11) and 84% (4092) had partners living with HIV. PrEP continuation was 57%, 44%, and 34% at 1, 3, and 6 months, respectively. Four unique trajectories of PrEP coverage were identified: (1) one‐fourth (1154) exhibited consistent high coverage throughout the year with 93%, 94%, 96%, and 67% continuing PrEP at months 1, 3, 6, and 12, respectively; (2) 13% (682) showed high coverage trajectory throughout 6 months but coverage rapidly declined thereafter (94%, 93%, 63%, and 10% continued at months 1, 3, 6, and 12, respectively); (3) 18.9% (918) exhibited moderate coverage trajectory with 91% of clients refilling PrEP at month 1 but nearly all dropped‐off thereafter (37%, 5%, and 4% continued at months 3, 6, and 12, respectively); and (4) 43.8% (2144) exhibited immediate discontinuation trajectory, in which nearly all did not have any subsequent PrEP refill. Overall, being female, older age, having partners living with HIV or of unknown HIV status were statistically associated with better PrEP continuation trajectories compared to the immediate discontinuation trajectory (p<0.05 for all). Conclusions: In this analysis of a real‐world PrEP implementation programme in Kenya, we found four distinct patterns of PrEP continuation, with one‐third of users exhibiting consistent high continuation throughout 12 months and two‐fifths with immediate discontinuation patterns. These data may help guide tailored interventions to support PrEP continuation in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The sample size calculations in Mugwanya et al. 2023 aimed to assess patterns of PrEP continuation and medication possession ratios during the first year of use.
“The sample size calculations aimed to assess patterns of PrEP continuation and medication possession ratios during the first year of use.”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [71]
The Methods > Analysis section (page unavailable) says the first-year analysis examined PrEP continuation and medication possession ratio. The paper does not say that sample size calculations were designed for that purpose; the Discussion instead describes the large study population as providing sufficient power to identify trajectories. (LLM, conf=0.86)
Experimental — accuracy not yet measuredMugwanya et al. 2023 used phased implementation, ensuring all clinics eventually received the intervention while enabling a rigorous evaluation of its effectiveness.
“Phased implementation, ensuring all clinics eventually received the intervention while enabling a rigorous evaluation of its effectiveness”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [71]
The Methods (Setting and population; page unavailable) describe a stepped-wedge cluster-randomized trial in 25 clinics, with PrEP delivery starting in stages. That supports phased implementation, but the paper does not explicitly say that every clinic eventually received the intervention or that this analysis evaluated the intervention’s effectiveness; its stated objective was to study PrEP continuation and coverage. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Irungu, E. M., Mugwanya, K. K., Mugo, N. R., Bukusi, E. A., Donnell, D., Odoyo, J., Wamoni, E., Peacock, S., Morton, J. F., Ngure, K., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00391-0 · Cited by 49
Self-citation
Flagged first, then by citations
Research works printed but not linked: 32
- 10.1056/NEJMoa1108524 · DOI · Paper page
- 10.1016/S0140-6736(13)61127-7 · DOI · Paper page
- 10.1056/NEJMoa1011205 · DOI · Paper page
- 10.1056/NEJMoa1110711 · DOI · Paper page
- 10.1056/NEJMoa1202614 · DOI
- 10.1371/journal.pmed.1003670 · DOI
- 10.1002/jia2.25962 · DOI
- Celum CL, 2019, HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery, J Int AIDS Soc, 22, 10.1002/jia2.25298 · DOI
- 10.1002/jia2.25636 · DOI
- 10.1016/S2352-3018(19)30335-2 · DOI
- 10.3389/frph.2021.683415 · DOI
- 10.1016/S2352-3018(19)30433-3 · DOI
- 10.1371/journal.pmed.1003492 · DOI
- 10.1097/QAD.0000000000000647 · DOI
- KMo Health.Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection in Kenya. 2016 Edition. Nairobi Kenya;2016.
- 10.1186/s13012-018-0809-7 · DOI · Paper page
- 10.1002/jia2.25799 · DOI
- 10.1037/1082-989X.7.2.147 · DOI · Paper page
- 10.1007/s10654-020-00615-6 · DOI
- 10.18637/jss.v078.i02 · DOI
- 10.1177/0011000016658097 · DOI
- 10.1097/QAI.0b013e31827e622d · DOI
- 10.21105/joss.01686 · DOI · Paper page
- 10.1080/13691058.2017.1367421 · DOI
- 10.1186/s43058-021-00228-4 · DOI
- Odoyo JB, 2019, Integrating PrEP into HIV care clinics could improve partner testing services and reinforce mutual support among couples: provider views from a PrEP implementation project in Kenya, J Int AIDS Soc, 22, 10.1002/jia2.25303 · DOI
- 10.1097/QAI.0000000000002625 · DOI
- 10.1007/s10461-018-2221-3 · DOI
- 10.1371/journal.pmed.1002099 · DOI
- 10.1002/jia2.25466 · DOI
- 10.1080/10705511.2016.1247646 · DOI · Paper page
- 10.1080/09540121.2020.1744507 · DOI
Cited by
Sorted by citations
Musa, Z. A., Akinsolu, F. T., Salako, A. O., Abodunrin, O. R., Ola, O. M., & Ezechi, O. C. (2026) · Frontiers in Epidemiology · doi:10.3389/fepid.2026.1529289
Metadata
- Authors
- Mugwanya, K. K., Palayew, A., Schaafsma, T., Irungu, E. M., Bukusi, E., Mugo, N., Morton, J., Odoyo, J., Ngure, K., Baeten, J. M., & for the Partners Scale‐Up Project
- Affiliations
- University of Washington (US)
- Kenya Medical Research Institute (KE)
- Corresponding author
- Mugwanya, Kenneth K.
- ORCID
- Venue
- Journal of the International AIDS Society
- Publisher
- Wiley
- Published
- 2023-07
- Volume
- 26
- Issue
- 7
- Pages
- e26137-e26137
- ISSN
- 1758-2652 (ISSN-L)
- PMC
- PMC10320042
- OpenAlex
- W4383186793
- Cited by
- 16
- References
- 2
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 3
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the International AIDS Society (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Mental Health
- Bill and Melinda Gates Foundation (OPP10556051)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- pre-exposure prophylaxis, PrEP continuation, PrEP coverage, PrEP discontinuation, medication possession ratio, HIV prevention, HIV-positive partners, Kenya, public health facilities, latent class analysis, stepped-wedge cluster randomized trial
- MeSH terms
- Latent Class Analysis, Adult, Female, Humans, Kenya, Male, HIV Infections, Anti-HIV Agents, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review